Telmisartan

When ATH:
C09CA07

Characteristic.

White or colorless crystalline powder, practically insoluble in water at pH 3 to 9, partially soluble in strong acids (with the exception of salt), soluble in strong alkalis.

Pharmacological action.
Antigipertenzivnoe.

Application.

Arterial hypertension.

Contraindications.

Hypersensitivity, obstruction of the biliary tract, severe liver and kidney, pregnancy, lactation.

Restrictions apply.

Childhood and adolescence (safety and efficacy in children and adolescents are not defined).

Pregnancy and breast-feeding.

Contraindicated in pregnancy. Before a planned pregnancy in advance is recommended to replace the drug other antihypertensive agents.

Category actions result in FDA - C (I trimester). (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

Category actions result in FDA - D (II and III trimesters).

At the time of treatment should stop breastfeeding.

Side effects.

From the nervous system and sensory organs: ≥ 1% - Headache, dizziness.

From the digestive tract: ≥ 1% - Nausea, dyspepsia, abdominal pain, diarrhea.

From the respiratory system: ≥ 1% -cough, pharyngitis, flu-like symptoms, lowering tolerance to infections of the upper respiratory tract.

Other: ≥ 1% -chest pain and back pain, myalgia, urinary tract infection, a decrease in hemoglobin, increased uric acid.

Cooperation.

Hydrochlorothiazide increases (mutually) hypotensive effect. When concomitant administration of ACE inhibitors, potassium-sparing diuretics and other drugs, can increase the level of potassium in the plasma, as well as potassium-containing food additives, especially in patients with renal insufficiency, increased risk of hyperkalemia. Increasing the concentration of lithium and digoxin in the blood.

Overdose.

Symptoms: gipotenziya.

Treatment: symptomatic and supportive therapy. Hemodialysis nyeeffyektivyen.

Dosing and Administration.

Inside, regardless of the meal, 20-40 mg/day for one admission, if necessary - up 80 mg. In patients with moderately impaired liver daily dose should not exceed 40 mg.

Precautions.

Be wary appoint patients with symptomatic renovascular hypertension, due to bilateral renal artery stenosis or stenosis of the renal artery only functioning kidney (increased risk of severe hypotension and renal failure). In patients with moderate renal impairment requires regular monitoring of serum creatinine and electrolytes (potassium) plasma. Caution must be exercised in the appointment of patients with reduced BCC and / or sodium deficiency (diuretics in the treatment of, limited supply of salt, diarrhea, rvote), stenosis of the aortic and mitral valves, with obstructive hypertrophic cardiomyopathy, moderate hepatic impairment, severe heart failure (requires constant monitoring of the level of potassium and creatinine serum), at IBS (possible development of acute coronary syndrome and myocardial infarction), gastric ulcer or duodenal ulcer in the acute stage, or others. diseases of the digestive tract (likely to cause gastrointestinal bleeding). Not recommended for use with primary aldosteronism, congenital fructose intolerance (1 tablet 80 mg comprises 338 mg electricity). Use caution to drivers of vehicles and people, skills relate to the high concentration of attention. At the same time taking digoxin or drugs lithium requires monitoring of their content in the blood serum.

Cooperation